The Rocks Beneath Your Feet Are Younger Than Your Parents and Made of Your Trash
Here's what you'll learn when you read this story:
The rock cycle naturally takes thousands to millions of years, but scientists just identified a new form of rock that cements in under four decades.
Researchers believe the natural cements found in industrial waste react with the ocean, leading to rapid cementation.
Experts were able to estimate the cementation timeline using modern objects found in the rock, some of which include a zipper, a King Charles V coin, and a soda tab.
Fossils are amazing; not only can they spark inspiration for iconic movie franchises (I'm looking at you, Jurassic Park), but they more importantly also provide accurate timestamps that help researchers piece together history from across millennia. Incredibly, scientists are starting to find examples of a new kind of fossil—well, sort of. Researchers from the University of Glasgow found modern society's detritus, including things like soda tabs, cemented inside a new form of rock. Published in the journal Geology, the study reconsiders everything we know about the rock cycle and how humans affect it.
Typically, rocks take thousands to millions of years to form, with processes like heating, compaction, and melting producing different types of rock over long periods of time. The recent study, however, found that the anthropoclastic rock cycle is forming rocks in just 35 years rather than hundreds. Researchers realized this when they were studying slag deposits—or byproducts from industrial production—at Derwent Howe in West Cumbria.
The region was formerly home to steel and iron-making plants, and scientists noticed irregular formations in the coastal cliffs, leading them to investigate 13 different sites in the area. Using methods including electron microscopy, X-ray diffraction, and Raman spectroscopy (chemical analysis), the team determined the slag is made of 'natural cements' like calcite, goethite, and brucite. They explain in the study that the rapid cementation is likely a reaction between the waste and the sea water.
Researchers were able to pinpoint just how rapid this new rock formation is by using the 'anthropogenic material'—or, more simply put, modern junk—they found hiding inside the rock.
'We found both a King George V coin from 1934 and an aluminium can tab with a design that we realised couldn't have been manufactured before 1989 embedded in the material,' John MacDonald, co-author of the study, explained in a press release. 'This gives us a maximum time frame of 35 years for this rock formation, well within the course of a single human lifetime.'
Other discoveries include a zipper, copper wire, and even a tire.
'This is an example in microcosm of how all the activity we're undertaking at the Earth's surface will eventually end up in the geological record as rock,' MacDonald continued, 'but this process is happening with remarkable, unprecedented speed.'
Researchers also expressed the environmental concerns the new rock form poses. The study suggests that we don't have as much time to dispose of loose waste material as we previously believed—and it only gets worse after it hardens. According to experts, excess anthropoclastic rocks could affect life both above and below the water's surface, especially as coastal ecosystems change with rising sea levels.
'What's remarkable here is that we've found these human-made materials being incorporated into natural systems and becoming lithified—essentially turning into rock—over the course of decades instead,' co-author Amanda Owen said in the release. 'It challenges our understanding of how a rock is formed, and suggests that the waste material we've produced in creating the modern world is going to have an irreversible impact on our future.'
While this isn't the first time the anthropoclastic rock cycle was recorded, it is the first time researchers could put a definitive timeline on the process. The team explained in the release that the effects of anthropoclastic rock aren't currently included in models of erosion and land management, which are crucial parts of combating climate change. In the future, the researchers hope to study more deposits throughout Europe and further understand the rapid anthropoclastic rock cycle.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Scientists are to examine whether drugs that are already in use could be repurposed to treat the symptoms of both Alzheimer's disease and Parkinson's in a new collaboration which aims to discover novel treatments at pace. Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
Yahoo
4 hours ago
- Yahoo
Scientists Scanned the Brains of Hardcore Gooners and Found Something Ominous
Watching a whole bunch of smut has some major side effects — and no, we're not just talking about stained bedsheets. In a new study published in the journal Frontiers in Human Neuroscience, researchers at the Chengdu Medical College in China found that people who watch a lot of pornography had lower cognitive performance and showed signs of neurological arousal akin to opioid addiction. It's new data in a swirling debate over whether watching porn — or how much — affects cognition, emotional regulation, and our relationships. The battle has raged on for years in academic journals, but has gained increasing prominence as a divisive political and social issue in recent years (complicating matters further, there's a broad medical consensus that masturbation is healthy.) The Chengdu researchers are squarely in the "porn sucks" category with this study. Using an experimental cohort of 21 heterosexual, mostly male college students — 16 who said in a survey they only watch adult content on occasion, and five who were described as having a "severe" internet porn addiction — the team used a brain imaging technique to measure how the habit was affecting cognition. Known as functional near-infrared spectroscopy or fNIRS, this imaging method looks at brain activity by shining a near-infrared light through the scalp and seeing how much of its light is absorbed by the hemoglobin in the brain. Using a fitted fNIRS cap and additional instruments that recorded facial expressions and vital signs, the researchers looked at the brain and body feedback coming from those 21 college students while they watched a 10-minute-long X-rated clip. Before and after the viewing session — in which the participants were asked to not masturbate, we should note — the students performed tests designed to measure cognitive function. The brain readings of the two groups turned out to be vastly different. The occasional porn watchers exhibited stronger neural connectivity in brain regions related to language, movement, and sensory processing. And the "gooners," to use cultural parlance for people who are seriously hooked on erotica, had heightened connectivity in regions related to executive function, addiction, and emotional regulation. The gooner squad also showed higher emotional and physiological arousal than their less-porn-watching counterparts, and their facial expressions when watching the clip showed a wide variety of emotions ranging from happiness to anger — though strangely, the study also found they appeared more "numb" than the lower-frequency group. In sum, the study suggests, the effects were similar to opioid users who experience intense calm, euphoria, and blurry perception. Physiologically, there were similarities between both groups during the viewing sessions — but the changes exhibited were often more dramatic in the gooners. Both groups had lowered heart rates during the session, but the effect was more pronounced in the more dedicated smut consumers. The same was true for the lowered cognitive performance both groups showed post-porn, which declined more steeply in the high-frequency porn watchers. These results aren't entirely surprising. A 2021 study found that problematic porn watchers suffer deficits in everything from working memory and decision-making to inhibition control and attention span; a 2014 paper found reductions in gray matter volume associated with consuming adult content. Though there will obviously need to be more and larger studies to figure out what's going on physically and neurologically with gooners, this research seems to demystify porn's effects on frequent watchers — not to mention an interesting new datapoint in the debate over the seriousness of porn addiction, too. More on porn: Government Website Caught Hosting "Gay Impregnation" Content
Medscape
6 hours ago
- Medscape
Early, Aggressive BP Lowering Tied to Better ICH Outcomes
Initiating intensive blood pressure (BP) lowering within a few hours of intracerebral hemorrhage (ICH) was associated with better neurologic outcomes, fewer serious adverse events, and better mortality compared to the more conservative standard treatment, new research confirmed. Best results were found when treatment was administered within 3 hours of ICH symptoms, a pooled analysis of the four Intensive BP Reduction in Acute Cerebral Hemorrhage Trials (INTERACT1-4) showed. While current guidelines set a target systolic BP of < 180 mm Hg within 1 hour of ICH symptom onset, the intensive treatment systolic target is < 140 Hg within 1 hour. The new findings were published online on June 18 in The Lancet Neurology . Timing Dependent? In addition to evaluating the safety and efficacy of early intensive treatment for ICH, the investigators also aimed to assess the impact of treatment timing. The INTERACT1-3 studies included 10,269 adults with acute ACH who presented within 6 hours of symptom onset and had a systolic BP of > 150 mm Hg. INTERACT4 included 1043 patients with suspected acute stroke who had a systolic BP of ≥ 150 mm Hg within 2 hours of symptom onset. In addition, 1029 study participants had a hemorrhagic form of stroke. All were randomly assigned to receive either intensive or guideline recommended BP-lowering treatment with locally available BP drugs within 1 hour. Scores on the modified Rankin scale were used to determine functional recovery, the primary outcome measure for the pooled analysis. Additionally, a CT substudy of nearly 3000 INTERACT participants was conducted to measure hematoma volume. Mean systolic BP rates at 1 hour were significantly lower for the intensive treatment group compared to the guideline group (149.6 mm Hg vs 158.8 mm Hg, respectively; P < .0001). Poor physical function, defined as a modified Rankin scale score of 3-6 at the end of follow-up, was significantly less likely after intensive BP lowering (odds ratio [OR], .85; P = .0001). The intensive group also had reduced odds of neurologic deterioration within 7 days compared to the guideline group (OR, .76; P = .0002), as well as lower odds of any serious adverse event (OR, .84; P = .0003) or death (OR, .83; P = .002). CT substudy results showed no significant effect on either relative or absolute hematoma growth in the first 24 hours from intensive vs guideline treatment. However, when intensive BP lowering was initiated within 3 hours of symptom onset, functional recovery was improved and hematoma growth was reduced in almost 25% of the patients with serial CT scans, investigators noted. Patients with mild-to-moderate severity, as measured by ICH scores, had even greater reductions in hematoma growth after early intensive BP-lowering treatment. The new pooled analysis of all four INTERACT trials confirms findings from INTERACT4, presented at the 2024 European Stroke Organization Conference Annual Meeting and reported by Medscape Medical News . 'Time Is Brain' In an accompanying editorial, David J. Werring, PhD, Department of Translational Neuroscience and Stroke, University College London Queen Square Institute of Neurology, London, noted that several previous studies showed no benefit of BP lowering in acute ischemic stroke, 'probably because acutely elevated blood pressure has a role in maintaining brain perfusion.' However, the pathophysiology of stroke from ICH 'is different, with a major role for hematoma expansion within the first few hours, a therapeutic target which might be reduced' by intensive BP lowering, he wrote. Still, Werring noted that possible benefits need to be weighed against possible risks; and he pointed out several study limitations, such as the low severity of ICH overall and the inclusion of INTERACT3 data, which may have introduced confounding from BP lowering being just one component of its treatment 'bundle,' alongside strict glucose control and anticoagulant reversal. 'Notwithstanding these important limitations, the data presented make a compelling case for ultra-early intensive blood pressure reduction as a potentially useful intervention to improve outcomes in people with acute ICH,' he wrote, adding that more research is needed. 'Meanwhile, the clear message from this meta-analysis is that earlier treatment is better, meaning that, once again, time is brain for patients with ICH,' Werring concluded.
